 but there are others throughout this document which may be identified by words such as expect anticipate intend plan believe will should could would project continue likely and similar expressions and include statements reflecting future results or guidance statements of outlook and expense accruals these matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected anticipated or implied the most significant of these risks and uncertainties are described below in item 1a risk factors and in exhibit 991 to this form 10k forwardlooking statements in this document speak only as of the date of this document except to the extent required by applicable law we undertake no obligation to update or revise any forwardlooking statement1table of contents cardinal health inc and subsidiariespart iitem 1 businessgeneralcardinal health inc is an ohio corporation formed in 1979 as used in this report we our us and similar pronouns refer to cardinal health inc and its subsidiaries unless the context requires otherwise we are a healthcare services company providing pharmaceutical and medical products and services that help pharmacies hospitals and other healthcare providers focus on patient care while reducing costs enhancing efficiency and improving quality we also provide medical products to patients in the homeour fiscal year ends on june 30 references to fiscal 2014 2013 and 2012 are to the fiscal years ended june 30 2014 2013 and 2012 respectively except as otherwise specified information in this form 10k is provided as of june 30 2014we report our financial results in two segments pharmaceutical and medicalpharmaceutical segmentin the united states the pharmaceutical segmentdistributes branded and generic pharmaceutical overthecounter healthcare and consumer products through its pharmaceutical distribution division to retailers including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers hospitals and other healthcare providers this divisionmaintains prime vendor relationships that streamline the purchasing process resulting in greater efficiency and lower costs for our customersrenders services to pharmaceutical manufacturers including distribution inventory management data reporting new product launch support and contract pricing and chargeback administrationprovides pharmacy services to hospitals and other healthcare facilities andfranchises retail pharmacies under the medicine shoppe and medicap brandsoperates nuclear pharmacies and cyclotron facilities through its nuclear pharmacy services division that manufacture prepare and deliver radiopharmaceuticals for use in nuclear imaging and other procedures in hospitals and physician offices anddistributes specialty pharmaceutical products provides services to pharmaceutical manufacturers thirdparty payors and healthcare providers supporting the development marketing distribution and payment for specialty pharmaceutical products and operates specialty pharmacies through its specialty solutions divisionin china the pharmaceutical segment distributes branded generic and specialty pharmaceutical overthecounter  healthcare and consumer products as well as provides logistics marketing and other services and operates directtopatient specialty pharmacies through cardinal health chinapharmaceutical distributionour pharmaceutical distribution division generates gross margin when the aggregate selling price to our customers exceeds the aggregate cost of products sold gross margin includes margin from our generic pharmaceutical programs margin from branded pharmaceutical distribution agreements and cash discounts margin from our generic pharmaceutical programs includes price discounts and rebates and may include price appreciation on some products our earnings on generic pharmaceuticals are generally highest during the period immediately following the initial launch of a generic product because generic pharmaceutical selling prices are generally highest during that period and tend to decline over time margin from branded pharmaceutical distribution agreements refers primarily to fees we receive for rendering a range of distribution and related services to manufacturers and also includes benefits from pharmaceutical price appreciationjoint venture with cvs caremarkin july 2014 we established red oak sourcing llc red oak sourcing a usbased generic pharmaceutical sourcing entity with cvs caremark corporation cvs with an initial term of 10 years both companies have contributed sourcing and supply chain expertise to the 5050 joint venture and have committed to source generic pharmaceuticals through arrangements negotiated by it red oak sourcing will negotiate generic pharmaceutical supply contracts on behalf of both companies but will not own products or hold inventory on behalf of either company we are required to pay 39 quarterly payments of 256 million to cvs commencing in october 2014 and only if certain milestones are achieved to pay additional predetermined amounts to cvs beginning in fiscal 2016 the fixed payments of 256 million will be expensed evenly commencing with the rampup of the venture which we expect to begin by the end of the first quarter of fiscal 2015 no physical assets were contributed by either company to red oak sourcing and minimal funding has been provided to capitalize the entityspecialty pharmaceutical products and serviceswe refer to products and services offered by our specialty solutions division as specialty pharmaceutical products and services the specialty solutions division distributes oncology rheumatology urology and other pharmaceutical products specialty pharmaceutical products and humanderived plasma products to hospitals physician offices and other healthcare providers provides consulting patient support logistics and other services to pharmaceutical manufacturers thirdparty payors and healthcare providers primarily supporting the development marketing distribution and payment for specialty pharmaceutical products and operates specialty 2table of contents cardinal health inc and subsidiaries   pharmacies our use of the terminology specialty pharmaceutical products and services may not be comparable to the use of that terminology by other industry participantspharmaceutical segment financial statementssee note 15 of the notes to consolidated financial statements for pharmaceutical segment revenue profit and assets for fiscal 2014 2013 and 2012medical segmentthe medical segment distributes a broad range of medical surgical and laboratory products to hospitals ambulatory surgery centers clinical laboratories physician offices and other healthcare providers in the united states canada and china and to patients in the home in the united states through our cardinal health at home division home division which was formerly known as our assuramed division this segment also manufactures sources and develops its own line of private brand medical and surgical products manufactured products include singleuse surgical drapes gowns and apparel exam and surgical gloves and fluid suction and collection systems the segment began to manufacture extravascular closure devices after the acquisition of access closure inc accessclosure in may 2014 we expect to expand the segments product offering for orthopedic cardiovascular and other procedures this segment also assembles and offers sterile and nonsterile procedure kits our manufactured products are sold directly or through thirdparty distributors in the united states canada europe and other regions internationally in addition the segment provides supply chain services including spend management distribution management and inventory management services to healthcare providersmedical segment financial statementssee note 15 of the notes to consolidated financial statements for medical segment revenue profit and assets for fiscal 2014 2013 and 2012 acquisitions and divestituresin the past five fiscal years we completed the following four larger acquisitionsdatecompanylocationlineof businessacquisitionpricein millions0313assuramed inctwinsburg ohmedical product distribution2070 1210kinray incwhitestone nypharmaceutical product distribution1336 1110cardinal health chinashanghai chinapharmaceutical and medical product distribution45810710healthcare solutionsholding llcellicott city mdspecialty pharmaceutical services52021includes the assumption of approximately 57 million in debt2includes 506 million in cash paid on the acquisition date and 14 million paid in fiscal 2012 and 2013 in connection with a contingent consideration obligation the contingent consideration obligation had an acquisition date fair value of 92 millionin addition we completed several smaller acquisitions during the last five fiscal years including accessclosure a manufacturer and distributor of extravascular closure devices in the united states in fiscal 2014 and futuremed healthcare products corporation a canadian medical product distributor in fiscal 2012during the past five fiscal years we also completed several divestitures including selling our united kingdombased martindale injectable manufacturing business in fiscal 2010 in addition effective august 31 2009 we separated our clinical and medical products businesses the carefusion spinoff through a distribution to our shareholders of 81 percent of the then outstanding common stock of carefusion corporation carefusion during fiscal 2010 and 2011 we disposed of the remaining shares of carefusion common stockcustomersour largest customer cvs accounted for 28 percent of our fiscal 2014 revenue in the aggregate our five largest customers including cvs accounted for 42 percent of our fiscal 2014 revenue our pharmaceutical distribution contract with walgreen co walgreens which was our second largest customer in fiscal 2013 and our third largest in fiscal 2014 expired in august 2013 walgreens accounted for 4 percent of our fiscal 2014 revenuein addition we have agreements with group purchasing organizations gpos that act as agents to negotiate vendor contracts on behalf of their members our two largest gpo relationships in terms of member revenue are with novation llc and premier purchasing partners lp sales to members of these two gpos under numerous contracts across all of our 3table of contents cardinal health inc and subsidiaries   businesses collectively accounted for 17 percent of our revenue in fiscal 2014supplierswe rely on many different suppliers products obtained from our five largest suppliers accounted for an aggregate of 24 percent of our revenue during fiscal 2014 but no single suppliers products accounted for more than 6 percent of revenue overall we believe our relationships with our suppliers are goodthe pharmaceutical distribution division is a party to distribution service agreements with pharmaceutical manufacturers these agreements have terms ranging from one year to five years most provide for an automatic renewal feature of one year some agreements allow either party and in some instances only the manufacturer to terminate the agreement without cause subject to a defined notice periodcompetitionwe operate in a highly competitive environment in the distribution of pharmaceuticals and related healthcare services we also operate in a highly competitive environment in the development manufacturing and distribution of medical and surgical products we compete on many levels including service offerings support services breadth of product lines and pricein the pharmaceutical segment we compete with wholesale distributors with national reach including mckesson corporation and amerisourcebergen corporation regional wholesale distributors selfwarehousing chains specialty distributors thirdparty logistics companies companies that provide services supporting the development marketing distribution and payment for specialty pharmaceutical products and nuclear pharmacies among others in addition the pharmaceutical segment has experienced competition from a number of organizations offering generic pharmaceuticals including telemarketers we also compete with manufacturers that sell all or part of their product offerings directlyin the medical segment we compete with many different national medical product distributors including owens amp minor inc mckesson corporation and medline industries inc we also compete with regional medical product distributors and companies that distribute medical products to patients in the home as well as thirdparty logistics companies in addition we compete with manufacturers that sell all or part of their product offerings directly competitors of the medical segments manufacturing and procedural kit businesses include diversified healthcare companies as well as companies that are more focused on specific product categoriesemployeesat june 30 2014 we had approximately 23900 employees in the united states and approximately 10100 employees outside of the united states overall we consider our employee relations to be good intellectual propertywe rely on a combination of trade secret patent copyright and trademark laws nondisclosure and other contractual provisions and technical measures to protect our products services and intangible assets we hold patents relating to some medical and surgical products and to distribution of our nuclear pharmacy products and service offerings we also operate under licenses for certain proprietary technologies and in certain instances we license our technologies to third parties we believe that we have taken all necessary steps to protect our proprietary rights but no assurance can be given that we will be able to successfully enforce or protect our rights in the event that they are infringed upon by a third party while all of these proprietary rights are important to our operations we do not consider any particular patent trademark license franchise or concession to be material to our overall businessregulatory mattersour business is highly regulated in the united states at both the federal and state level and in foreign countries depending upon their specific business our subsidiaries may be subject to regulation by government entities includingthe us food and drug administration the fdathe us drug enforcement administration the deathe us nuclear regulatory commission the nrcthe us department of health and human servicesthe us federal trade commissionus customs and border protectionstate boards of pharmacystate controlled substance agenciesstate health departments insurance departments or other comparable state agencies andforeign agencies that are comparable to those listed abovethese regulatory agencies have a variety of civil administrative and criminal sanctions at their disposal for failure to comply with applicable legal or regulatory requirements they can suspend our ability to distribute products or can initiate product recalls they can seize products or impose criminal civil and administrative sanctions and they can seek injunctions to halt the manufacture and distribution of productsdistributionthe fda dea and various state authorities regulate the marketing purchase storage and distribution of pharmaceutical and medical products under various state and federal statutes including the prescription drug marketing act of 1987 and the federal controlled substances act the csa which governs the sale packaging storage and distribution of controlled substances wholesale distributors of controlled substances must hold valid dea registrations and statelevel licenses meet various security and operating standards and comply with the 4table of contents cardinal health inc and subsidiaries   csa in may 2014 our lakeland florida pharmaceutical distribution centers dea registration to distribute controlled substances was reinstated in accordance with a settlement agreement that we had entered into with the dea in may 2012 as further discussed in note 9 of the notes to consolidated financial statementsmanufacturing and marketingour subsidiaries that manufacture and source medical devices or pharmaceuticals are subject to regulation by the fda or comparable foreign agencies that administer regulations such as compliance with good manufacturing practices and quality systemsthe fda and other domestic and foreign governmental agencies administer requirements that cover the design testing safety effectiveness manufacturing labeling promotion and advertising distribution importation and postmarket surveillance of some of our manufactured products we need specific approval or clearance from regulatory authorities before we can market and sell many of our products in particular countries even after we obtain approval or clearance to market a product the product and our manufacturing processes are subject to continued regulatory oversight it can be costly and timeconsuming to obtain regulatory approvals or clearances to market a medical device and such approvals or clearances might not be granted on a timely basis if at allfrom time to time we may determine that products we manufacture or market do not meet our specifications regulatory requirements or published standards when we or a regulatory agency identify a quality or regulatory issue we investigate and take appropriate corrective action which may include withdrawing the product from the market correcting the product at the customer location revising product labeling and notifying customersnuclear pharmacies and related businessesour nuclear pharmacies and cyclotron facilities require licenses or permits and must abide by regulations issued by the nrc applicable state boards of pharmacy and the radiologic health agency or department of health of each state in which we operate in addition our cyclotron facilities must comply with the fdas good manufacturing practices regulations for positron emission tomography or pet drugsprescription drug tracing and supply chain integrityin november 2013 the us congress enacted the drug supply chain security act this law establishes a phasedin national system for tracing pharmaceutical products through the pharmaceutical distribution supply chain to prevent the introduction of counterfeit adulterated or mislabeled drugs the first phase of implementation will begin january 1 2015 and upon full implementation in 2023 supply chain stakeholders will participate in an electronic interoperable prescription drug tracing system   government healthcare programswe are subject to us federal healthcare fraud and abuse laws these laws generally prohibit persons from soliciting offering receiving or paying any compensation in order to induce someone to order or purchase items or services that are in any way paid for by medicare medicaid or other federallyfunded healthcare programs they also prohibit submitting or causing to be submitted any fraudulent claim for payment by the federal government there are often similar state healthcare fraud and abuse laws that apply to medicaid and other statefunded healthcare programs violations of these laws may result in criminal or civil penalties as well as breach of contract claims and qui tam actions false claims cases initiated by private parties purporting to act on behalf of federal or state governmentsour home division is a medicarecertified supplier and participates in state medicaid programs with respect to a small portion of its business it must meet quality standards and maintain accreditation to receive government reimbursement and must comply with applicable billing payment and recordkeeping requirements failure to comply with quality standards and billing requirements could result in civil or criminal sanctions including the loss of our ability to participate in medicare medicaid and other federal and state healthcare programsin addition our us federal and state government contracts are subject to specific procurement regulations failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts or our suspension or debarment from government contract workhealth and personal information practicessome of our businesses collect handle and maintain patientidentifiable healthcare information the health insurance portability and accountability act of 1996 as augmented by the health information technology for economic and clinical health act as well as some state laws regulate the use and disclosure of patientidentifiable health information including requiring specified privacy and security measures federal and state officials have increasingly focused on how patientidentifiable healthcare information should be handled secured and disclosedsome of our businesses collect handle and maintain other sensitive personal information that is subject to federal and state laws protecting such information security and disclosure of personal information is also highly regulated in many other countries in which we operateenvironmental health and safety lawsin the united states and other countries we are subject to various federal state and local environmental laws as well as laws relating to safe working conditions laboratory and manufacturing practices5table of contents cardinal health inc and subsidiaries   laws relating to foreign trade and operationsus and foreign laws require us to abide by standards relating to the import and export of finished goods raw materials and supplies and the handling of information we also must comply with various export control and trade embargo laws which may require licenses or other authorizations for transactions within some countries or with some counterpartiessimilarly we are subject to us and foreign laws concerning the conduct of our foreign operations including the us foreign corrupt practices act chinese anticorruption laws and other foreign antibribery laws among other things these laws generally prohibit companies and their intermediaries from offering promising or making payments to officials of foreign governments for the purpose of obtaining or retaining businessregulation in chinaour china operations are subject to national regional and local regulations including licensing and regulatory requirements of the china national health and family planning commission the state administration of industry and commerce the ministry of commerce the ministry of finance the china food and drug administration the national development and reform commission and the general administration of customsother informationalthough our agreements with manufacturers sometimes require us to maintain inventory levels within specified ranges our distribution businesses are generally not required by our customers to maintain particular inventory levels other than as needed to meet service level requirements certain supply contracts with us government entities require us to maintain sufficient inventory to meet emergency demands but we do not believe those requirements materially affect inventory levelsour customer return policies generally require that the product be physically returned subject to restocking fees we only allow customers to return products that can be added back to inventory and resold at full value or that can be returned to vendors for creditwe offer market payment terms to our customersrevenue and longlived assets by geographic areasee note 15 of the notes to consolidated financial statements for revenue and longlived assets by geographic areaavailable information our annual report on form 10k quarterly reports on form 10q current reports on form 8k and amendments to those reports are available free of charge on our website wwwcardinalhealthcom under the investorsfinancial reportingsec filings caption as soon as reasonably practicable after we electronically file them with or furnish them to the securities and exchange commission the sec you may read and copy any materials we file with the sec at the secs public reference room at 100 f street ne washington dc 20549 you may obtain information on the operation of the public reference room by calling the sec at 1800sec0330 the sec also maintains a website wwwsecgov where you can search for annual quarterly and current reports proxy and information statements and other information regarding us and other public companiesitem 1a risk factorsthe risks described below could materially and adversely affect our results of operations financial condition liquidity and cash flows these are not the only risks we face our businesses also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operationsthe us healthcare environment is changing in many ways some of which may not be favorable to usthe healthcare industry continues to undergo significant changes designed to increase access to medical care improve safety contain costs and increase efficiencies medicare and medicaid reimbursement levels have declined the use of managed care has increased distributors manufacturers healthcare providers and pharmacy chains have consolidated and have formed strategic alliances and large purchasing groups are prevalent the industry also has experienced a shift away from traditional healthcare venues like hospitals and into clinics and physician offices and in some cases patients homes we could be adversely affected directly or indirectly if our customers are adversely affected by these and other changes in the delivery or pricing of or reimbursement for pharmaceuticals medical devices or healthcare serviceswe could suffer the adverse effects of competitive pressuresas described in greater detail in item 1 business above we operate in markets that are highly competitive because of competition our businesses face continued pricing pressure from our customers and suppliers if we are unable to offset margin reductions caused by these pricing pressures through steps such as sourcing or cost control measures or additional service offerings our results of operations and financial condition could be adversely affectedin addition in recent years the healthcare industry has continued to consolidate further consolidation among our customers and suppliers could give the resulting enterprises greater bargaining power which may adversely impact our results of operationsour pharmaceutical segments margin may be affected by prices established by manufacturers fewer or less profitable generic pharmaceutical launches and other factors that are beyond our controlas described in greater detail in item 1 business above gross margin in our pharmaceutical segment is impacted by generic and branded pharmaceutical price appreciation and the number 6table of contents cardinal health inc and subsidiaries   and value of generic pharmaceutical launches in past years these items have been substantial drivers of pharmaceutical segment profitprices for generic pharmaceuticals generally decline over time but at times some generic products experience price appreciation which positively impacts our margins the frequency and magnitude of future generic product price appreciation is uncertain prices for branded pharmaceuticals on the other hand generally increase over time the frequency and magnitude of branded product price appreciation also is uncertain and branded manufacturers may determine not to increase prices or to implement only modest increases which can limit our marginthe number of new generic pharmaceutical launches varies from year to year and the margin impact of new launches varies from product to product fewer generic pharmaceutical launches or launches that are less profitable than those previously experienced will have an adverse effect on our yearoveryear margins our business is subject to rigorous regulatory and licensing requirementsthe healthcare industry is highly regulated as described in greater detail in item 1 business above we are subject to regulation in the united states at both the federal and state level and in china and other foreign countries if we fail to comply with these regulatory requirements or if allegations are made that we fail to comply our results of operations and financial condition could be adversely affectedto lawfully operate our businesses we are required to obtain and hold permits licenses and other regulatory approvals from and to comply with operating and security standards of numerous governmental bodies failure to maintain or renew necessary permits licenses or approvals or to comply with required standards could have an adverse effect on our results of operations and financial conditionproducts that we manufacture source distribute or market are required to comply with regulatory requirements noncompliance or concerns over noncompliance may result in suspension of our ability to distribute import or manufacture products product recalls or seizures or criminal or civil sanctions in addition it can be costly and timeconsuming to obtain regulatory approvals to market a medical device and such approvals might not be granted on a timely basis if at allwe are required to comply with laws relating to healthcare fraud and abuse the requirements of these laws are extremely complex and subject to varying interpretations it is possible that regulatory authorities could challenge our policies and practices which may adversely affect our operations results of operations and financial condition if we fail to comply with these laws we could be subject to federal or state government investigations  or qui tam actions false claims cases initiated by private parties purporting to act on behalf of federal or state governments which could result in civil or criminal sanctions including the loss of licenses or the ability to participate in medicare medicaid and other federal and state healthcare programs our home division is a medicarecertified supplier and participates in state medicaid programs with respect to a small portion of its business its failure to comply with quality standards and billing requirements could result in civil or criminal sanctions including the loss of our ability to participate in medicare and other federal and state healthcare programsour government contracts are subject to specific procurement regulations failure to comply with applicable rules or regulations or with contractual or other requirements may result in monetary damages and criminal or civil penalties as well as termination of our government contracts or our suspension or debarment from government contract workour global operations are required to comply with the us foreign corrupt practices act chinese anticorruption laws and similar antibribery laws in other jurisdictions and us and foreign export control trade embargo and customs laws if we fail to comply with any of these laws we could suffer civil or criminal sanctionsour china operations are subject to national regional and local regulations the regulatory environment in china is evolving and officials in the chinese government exercise broad discretion in deciding how to interpret and apply regulations it is possible that the chinese governments current or future interpretation and application of existing or new regulations will negatively impact our china operations result in regulatory investigations or lead to fines or penaltiescvs caremark is a large customer that generates a significant amount of our revenueour sales and credit concentration is significant cvs accounted for 28 percent of our fiscal 2014 revenue and 22 percent of our gross trade receivable balance at june 30 2014 if cvs were to terminate the agreement due to an alleged default by us default in payment or significantly reduce its purchases of our products and services our results of operations and financial condition could be adversely affected the anticipated benefits of our generic pharmaceutical sourcing joint venture with cvs caremark may not be realized in july 2014 we established the red oak sourcing joint venture with cvs with an initial term of 10 years red oak sourcing will negotiate generic pharmaceutical supply contracts on behalf of both companies we are required to pay 39 quarterly payments of 256 million to cvs commencing in october 2014 without regard to the level of benefits we receive if the benefits of the joint venture do not exceed our required payments to cvs our 7table of contents cardinal health inc and subsidiaries   results of operations and financial condition could be adversely affectedwe could be subject to adverse changes in the tax laws or challenges to our tax positionswe are a large multinational corporation with operations in the united states and many foreign countries as a result we are subject to the tax laws of many jurisdictions from time to time legislative initiatives are proposed in the united states such as the repeal of lastin firstout or lifo treatment of inventory or a change in the current us taxation of income earned by foreign subsidiaries that could adversely affect our tax positions effective tax rate tax payments or financial condition tax laws are extremely complex and subject to varying interpretations tax authorities have challenged some of our tax positions and it is possible that they will challenge others these challenges may adversely affect our effective tax rate tax payments or financial conditionour business and operations depend on the proper functioning of information systems and critical facilitieswe rely on our information systems to obtain rapidly process analyze and manage data tofacilitate the purchase and distribution of inventory items from numerous distribution centersreceive process and ship orders on a timely basismanage the accurate billing and collections for thousands of customersprocess payments to suppliersfacilitate the manufacturing and assembly of medical products andgenerate financial informationour business also depends on the proper functioning of our critical facilities including our national logistics center our results of operations could be adversely affected if our information systems or critical facilities or our customers access to them are interrupted these systems or facilities are damaged or these systems or facilities fail whether due to physical disruptions such as fire natural disaster pandemic or power outage or due to cyber security incidents or other actions of third parties our business relies on the secure transmission storage and hosting of sensitive information including patientidentifiable health information financial information and other sensitive information relating to our customers company and workforce the techniques used by those seeking to obtain unauthorized access to our information systems or disable them degrade their service or sabotage them change frequently in addition these techniques may be difficult to detect for a long time and often are not recognized until launched against a target as a result we may be unable to anticipate these techniques or to implement adequate preventative measures any compromise of our information systems or those of a thirdparty service  provider including the unauthorized access use or disclosure of sensitive information could adversely impact our operations results of operations or our ability to satisfy legal requirements including those related to patientidentifiable health information because of the nature of our business we may become involved in legal proceedings that could adversely impact our cash flows or results of operationsdue to the nature of our businesses which includes the manufacture and distribution of healthcare products we may from time to time become involved in disputes or legal proceedings for instance some of the products that we manufacture or distribute may be alleged to cause personal injury or violate the intellectual property rights of another party subjecting us to product liability or infringement claims our medical segments manufacturing businesses operate in an industry characterized by extensive intellectual property litigation patent litigation is costly to defend and can result in significant damage awards and injunctions that could prevent the manufacture and sale of affected products or force us to make royalty payments in order to continue selling the affected products we also may be named in breach of contract claims or qui tam actions false claims cases initiated by private parties purporting to act on behalf of federal or state governments litigation is inherently unpredictable and the unfavorable resolution of one or more of these legal proceedings could adversely affect our cash flows or results of operations acquisitions can have unanticipated resultsan important element of our growth strategy has been to acquire other businesses that expand or complement our existing businesses in fiscal 2014 we spent 519 million to acquire other businesses acquisitions involve risks we may overpay for a business or fail to realize the synergies and other benefits we expect from the acquisition future developments may impair the value of our purchased goodwill or intangible assets or we may encounter unforeseen accounting internal control regulatory or compliance issueswe depend on certain suppliers to make their raw materials and products available to us and are subject to fluctuations in costs of raw materials and productswe depend on the availability of various components compounds raw materials including radioisotopes and energy supplied by others for our operations any of our supplier relationships could be interrupted due to events beyond our control including natural disasters or could be terminated a sustained supply interruption could have an adverse effect on our business our manufacturing businesses use oilbased resins cotton latex and other commodities as raw materials in many products prices of oil and gas also affect our distribution and transportation costs prices of these commodities are volatile 8table of contents cardinal health inc and subsidiaries   and can fluctuate significantly causing our costs to produce and distribute our products to fluctuate due to competitive dynamics and contractual limitations we may be unable to pass along cost increases through higher prices if we cannot fully offset cost increases through other cost reductions or recover these costs through price increases or surcharges our results of operations could be adversely affectedour global operations are subject to economic political and currency risksour global operations are affected by local economic environments including inflation recession currency volatility and competition political changes also can disrupt our global operations as well as our customers and suppliers in a particular location we may not be able to hedge or obtain insurance to protect us against these risks and any hedges or insurance may be expensive and may not successfully mitigate these riskseconomic conditions may adversely affect demand for our products and servicesdeterioration in general economic conditions in the united states and other countries in which we do business could adversely affect the amount of prescriptions filled and the number of medical procedures undertaken and therefore reduce purchases of our products and services by our customers which could adversely affect our results of operationsitem 1b unresolved staff commentsnot applicableitem 2 propertiesin the united states at june 30 2014 the pharmaceutical segment operated 21 primary pharmaceutical distribution facilities and one national logistics center three specialty distribution facilities and over 140 nuclear pharmacy facilities the medical segment operated 60 medicalsurgical distribution assembly manufacturing and other facilities our us operating facilities are located in 45 states and in puerto ricooutside the united states at june 30 2014 our medical segment operated over 20 facilities in canada the dominican republic malaysia malta mexico and thailand that engage in manufacturing distribution or research in addition our pharmaceutical and medical segments utilized various distribution and pharmacy facilities in china at june 30 2014 we owned over 70 operating facilities and leased more than 200 operating facilities our principal executive offices are headquartered in an owned building located at 7000 cardinal place in dublin ohio we consider our operating properties to be in satisfactory condition and adequate to meet our present needs however we regularly evaluate operating properties and may make further additions and improvements or consolidate locations as we seek opportunities to expand or enhance the efficiency of our businessitem 3 legal proceedingsin addition to the proceedings described below the legal proceedings described in note 9 of the notes to consolidated financial statements are incorporated in this item 3 legal proceedings by referencein june 2012 henry stanley jr a purported shareholder filed a derivative action in the us district court for the southern district of ohio against the current and certain former members of our board of directors the complaint alleged that the defendants breached their fiduciary duties in connection with the deas past suspensions of our distribution centers registrations to distribute controlled substances in october 2012 the us district court dismissed the derivative action with prejudice and in august 2013 the us court of appeals affirmed the decision in september 2013 the same plaintiff made demand on our board of directors to take action against current and certain former members of our board of directors based on the allegations made in the derivative action a special committee of independent directors investigated the allegations made in the demand after receiving and evaluating the special committees findings and recommendations our board of directors determined in february 2014 that pursuing the claims set forth in the demand was not in the best interest of the company in may 2014 another purported shareholder made a similar demand on our board of directors our board of directors through the special committee is in the process of reviewing the allegations made in this new demanditem 4 mine safety disclosuresnot applicable9table of contents cardinal health inc and subsidiaries   executive officers of the registrantthe following is a list of our executive officers as of july 31 2014nameagepositiongeorge s barrett59chairman and chief executive officerjeffrey w henderson49chief financial officermichael c kaufmann51chief executive officer pharmaceutical segmentdonald m casey jr54chief executive officer medical segmentcraig s morford55chief legal and compliance officercarole s watkins54chief human resources officermark r blake43executive vice president strategy and corporate developmentstephen t falk49executive vice president general counsel and corporate secretarythe business experience summaries provided below for our executive officers describe positions held during the last five years unless otherwise indicatedmr barrett has served as chairman and chief executive officer since august 2009 from january 2008 to august 2009 he served as vice chairman of cardinal health and chief executive officer healthcare supply chain services mr henderson has served as chief financial officer since may 2005 in june 2014 we announced that mr henderson has decided to retire from the company to ensure an orderly transition he will remain with the company until august 2015 and will step down as chief financial officer when we name a successor to that role  mr kaufmann has served as chief executive officer pharmaceutical segment since august 2009 from april 2008 until august 2009 he served as our group president pharmaceutical supply chainmr casey has served as chief executive officer medical segment since april 2012 before joining us he served as chief executive officer of the gary and mary west wireless health institute a nonprofit research organization focused on lowering the cost of healthcare through novel technology solutions from march 2010 to march 2012 prior to that he served as world wide franchise chairman comprehensive care at johnson amp johnson a developer and manufacturer of health care products from 2007 to 2009 mr morford has served as chief legal and compliance officer since may 2009 ms watkins has served as chief human resources officer since 2000mr blake has served as executive vice president strategy and corporate development since october 2009 from august 2006 until october 2009 he held various business development positions with medco health solutions inc a pharmacy benefits management services company including vice president business development and senior director business developmentmr falk has served as executive vice president general counsel and corporate secretary since may 200910table of contents cardinal health inc and subsidiariespart iiaitem 5 market for registrants common equity related stockholder matters and issuer purchases of equity securitiesour common shares are listed on the new york stock exchange under the symbol cah the following table reflects the range of the reported high and low closing prices of our common shares as reported on the new york stock exchange composite tape and the per share dividends declared for the fiscal years ended june 30 2014 and 2013 it also reflects the range of the reported high and low closing prices of our common shares from july 1 2014 through the period ended on july 31 2014 and the per share dividends declared from july 1 2014 through the period ended on august 6 2014 high low dividendsfiscal 2013     quarter ended     september 30 20124350 3775 02375december 31 20124265 3929 02750march 31 20134709 4162 02750june 30 20134876 4185 03025      fiscal 2014     quarter ended     september 30 20135357 4702 03025december 31 20136748 5295 03025march 31 20147354 6526 03025june 30 20147131 6380 03425      fiscal 20157275 6959 03425at july 31 2014 there were approximately 10241 shareholders of record of our common shareswe anticipate that we will continue to pay quarterly cash dividends in the future the payment and amount of future dividends remain however within the discretion of our board of directors and will depend upon our future earnings financial condition capital requirements and other factors issuer purchases of equity securities        periodtotal numberof sharespurchased 1 average price paid per share total number of sharespurchasedas part of publicly announced programs 2 approximatedollar value ofshares that mayyet be purchasedunder the programs 2in millionsapr 2014252 6923  1011may 20141661576 6732 1661405 900jun 20142513482 6864 2513288 727total4175310 6812 4174693 7271includes 252 171 and 194 common shares purchased in april may and june 2014 respectively through a rabbi trust as investments of participants in our deferred compensation plan2on august 8 2012 our board of directors approved a 750 million share repurchase program which expires on august 31 2015 during the three months ended june 30 2014 we repurchased 11 million of our common shares the remaining amount under this program on october 29 2013 our board of directors approved a 10 billion share repurchase program which expires on december 31 2016 during the three months ended june 30 2014 we repurchased 273 million of our common shares under this program on august 6 2014 our board of directors authorized an additional 10 billion under this share repurchase program11table of contents cardinal health inc and subsidiaries   performance graphfive year performance graphthe following line graph compares the cumulative total return of our common shares with the cumulative total return of the standard amp poors composite500 stock index the sampp 500 index and the standard amp poors composite500 healthcare index the sampp 500 healthcare index the line graph assumes in each case an initial investment of 100 on june 30 2009 based on the market prices at the end of each fiscal year through and including june 30 2014 and reinvestment of dividends the sampp 500 index and sampp 500 healthcare index investments are weighted on the basis of market capitalization at the beginning of each period we have adjusted the market price of our common shares prior to august 31 2009 to reflect the carefusion spinoff on august 31 2009  june 30 200920102011201220132014cardinal health inc100001566721608204092353134854sampp 500 index100001144214951157611900523675sampp 500 healthcare index10000108991400915376196422554412table of contents cardinal health inc and subsidiaries    item 6 selected financial datathe consolidated financial data below includes all business combinations as of the date of acquisition that occurred during these periods the following selected consolidated financial data should be read in conjunction with the consolidated financial statements and related notes and item 7 managements discussion and analysis of financial condition and results of operationsin millions except per common share amounts2014 2013 1 2012 2011 2010earnings data         revenue91084 101093 107552 102644 98503          earnings from continuing operations1163 335 1070 966 587earningsloss from discontinued operations 23 1 1 7 55net earnings1166 334 1069 959 642          basic earningsloss per common share         continuing operations341 098 310 277 164discontinued operations 2001   002 015net basic earnings per common share342 098 310 275 179          diluted earningsloss per common share         continuing operations337 097 306 274 162discontinued operations 2001   002 015net diluted earnings per common share338 097 306 272 177          cash dividends declared per common share12500 10900 08825 08000 07200          balance sheet data         total assets26033 25819 24260 22846 19990longterm obligations less current portion3171 3686 2418 2175 1896shareholders equity6401 5975 6244 5849 52761during the fourth quarter of fiscal 2013 we recognized a noncash goodwill impairment charge of 829 million 799 million net of tax related to our nuclear pharmacy services division2on august 31 2009 we separated the clinical and medical products businesses from our other businesses through a pro rata distribution to shareholders of 81 percent of the then outstanding common stock of carefusion and met the criteria for classification of these businesses as discontinued operations13table of contents cardinal health inc and subsidiariesfinancial reviewitem 7 managements discussion and analysis of financial condition and results of operationsthe discussion and analysis presented below refers to and should be read in conjunction with the consolidated financial statements and related notes included in this form 10k unless otherwise indicated throughout this managements discussion and analysis of financial condition and results of operations we are referring to our continuing operationsoverviewwe are a healthcare services company providing pharmaceutical and medical products and services that help pharmacies hospitals and other healthcare providers focus on patient care while reducing costs enhancing efficiency and improving quality we also provide medical products to patients in the home we report our financial results in two segments pharmaceutical and medicalduring fiscal 2014 revenue decreased 10 percent to 911 billion largely due to the previously disclosed expiration of our pharmaceutical distribution contract with walgreen co walgreens on august 31 2013gross margin increased 5 percent to 52 billion reflecting the positive impact of acquisitions and strong performance from generic programs offset in part by the impact of the walgreens contract expirationoperating earnings increased to 19 billion and earnings from continuing operations increased to 12 billion due primarily to an 829 million 799 million net of tax noncash goodwill impairment charge related to our nuclear pharmacy services division in fiscal 2013our cash and equivalents balance was 29 billion at june 30 2014 compared to 19 billion at june 30 2013 the increase in cash and equivalents during fiscal 2014 was driven by net cash provided by operating activities of 25 billion which includes the decrease in our net working capital associated with the walgreens contract expiration net cash provided by operating activities was deployed for share repurchases 673 million acquisitions 519 million and dividends 415 million we plan to continue to execute a balanced deployment of available capital to position ourselves for sustainable competitive advantage and to enhance shareholder valuewalgreens contractthe walgreens contract expiration unfavorably impacted periodoverperiod comparisons of revenue and operating earnings for fiscal 2014 but favorably affected net cash provided by operating activities due to a significant reduction in net working capital because revenue from walgreens was 33 billion during the first quarter of fiscal 2014 we expect the  contract expiration to have an adverse impact on our periodoverperiod comparisons of revenue and operating earnings during the first quarter of fiscal 2015joint venture with cvs caremarkin july 2014 we established red oak sourcing llc red oak sourcing a usbased generic pharmaceutical sourcing entity with cvs caremark corporation cvs with an initial term of 10 years both companies have contributed sourcing and supply chain expertise to the 5050 joint venture and have committed to source generic pharmaceuticals through arrangements negotiated by it red oak sourcing will negotiate generic pharmaceutical supply contracts on behalf of both companies but will not own products or hold inventory on behalf of either company we are required to pay 39 quarterly payments of 256 million to cvs commencing in october 2014 and only if certain milestones are achieved to pay additional predetermined amounts to cvs beginning in fiscal 2016 the fixed payments of 256 million will be expensed evenly commencing with the rampup of the venture which we expect to begin by the end of the first quarter of fiscal 2015 no physical assets were contributed by either company to red oak sourcing and minimal funding has been provided to capitalize the entityacquisitionswe have completed several acquisitions since july 1 2011 the largest of which were assuramed inc assuramed in fiscal 2013 and access closure inc accessclosure in fiscal 2014 on may 9 2014 we completed the acquisition of accessclosure for 320 million in an allcash transaction we funded the acquisition with cash on hand the acquisition of accessclosure a manufacturer and distributor of extravascular closure devices expands the medical segments portfolio of selfmanufactured products on march 18 2013 we completed the acquisition of assuramed for 207 billion net of cash acquired in an allcash transaction we funded the acquisition through the issuance of 13 billion in fixed rate notes and cash on hand the acquisition of assuramed a provider of medical supplies to homecare providers and patients in the home expands medical segments ability to serve this patient base the assuramed division is now known as our cardinal health at home division home division this acquisition increased revenue and operating earnings during fiscal 2014 the increase in amortization and other acquisitionrelated costs during fiscal 2014 was primarily due to intangible assets from this acquisition we expect the amortization of acquisitionrelated intangible assets to continue to be a significant expense in future periodssee note 2 of the notes to consolidated financial statements for additional information on these acquisitions14table of contents cardinal health inc and subsidiariesfinancial review continuedgoodwillas part of our annual goodwill impairment test during fiscal 2013 we concluded that the entire goodwill amount of our nuclear pharmacy services division was impaired resulting in a noncash impairment charge of 829 million 799 million net of tax this impairment charge did not impact our liquidity cash flows from operations or compliance with debt covenants see note 5 of the notes to consolidated financial statements for additional informationrestructuringon january 30 2013 we announced a restructuring plan within our medical segment under this restructuring plan among other things we have reorganized our medical segment moved production of procedure kits from our facility in waukegan illinois to other facilities and consolidated office space in waukegan illinois in addition we are selling property in waukegan illinois and we are exiting our gamma sterilization business in el paso texas we currently estimate the total costs associated with this restructuring plan to be approximately 74 million on a pretax basis of which 18 million and 51 million was recognized in fiscal 2014 and fiscal 2013 respectively trendswithin our pharmaceutical segment pharmaceutical price appreciation on some generic products positively impacted our margins during fiscal 2014 but the frequency and magnitude of future generic product price appreciation is uncertain and the impact on earnings may be less in fiscal 2015 than in fiscal 2014results of operationsrevenue revenue changein millions2014 2013 2012 2014 2013pharmaceutical80110 91097 97925 12 7medical10962 10060 9642 9  4 total segment revenue91072 101157 107567 10 6corporate12 64 15 nm nmtotal revenue91084 101093 107552 10 6fiscal 2014 compared to fiscal 2013pharmaceutical segmentrevenue for fiscal 2014 compared to fiscal 2013 was negatively impacted by the walgreens contract expiration 169 billion and by the expiration of our pharmaceutical distribution contract with express scripts inc express scripts on september 30 2012 20 billion this decrease was partially offset by sales growth from existing pharmaceutical distribution customers 71 billionmedical segmentrevenue for fiscal 2014 compared to fiscal 2013 reflects the benefit of acquisitions 816 million fiscal 2013 compared to fiscal 2012pharmaceutical segmentrevenue for fiscal 2013 compared to fiscal 2012 was negatively impacted by the expiration of our pharmaceutical distribution contract with express scripts approximately 67 billion revenue from existing pharmaceutical distribution customers decreased by approximately 36 billion primarily as a result of brandtogeneric pharmaceutical conversions the decrease was partially offset by increased pharmaceutical distribution revenue from new customers approximately 38 billion and revenue growth within our specialty solutions division 961 million medical segmentrevenue for fiscal 2013 compared to fiscal 2012 reflects the benefit of acquisitions 459 millioncost of products soldas a result of the same factors affecting the change in revenue cost of products sold decreased 102 billion 11 percent and 68 billion 7 percent during fiscal 2014 and fiscal 2013 respectively see the gross margin discussion below for additional drivers impacting cost of products soldgross margin gross margin changein millions2014 2013 2012 2014 2013gross margin5161 4921 4541 5 8fiscal 2014 compared to fiscal 2013gross margin increased during fiscal 2014 compared to fiscal 2013 240 million reflecting the positive impact of acquisitions 221 milliongross margin for fiscal 2014 was positively impacted by 32 million due to sales growth which primarily reflects growth from existing customers and was largely offset by the impact of the walgreens contract expirationgross margin rate apart from the impact of the walgreens contract expiration was flat for fiscal 2014 gross margin rate was positively impacted by strong performance from generic programs including the impact of generic pharmaceutical price appreciation and was adversely impacted by customer pricing changesfiscal 2013 compared to fiscal 2012gross margin increased in fiscal 2013 compared to fiscal 2012 driven by strong performance in our generic pharmaceutical programs 350 million and acquisitions 131 million increased margin from branded pharmaceutical distribution agreements exclusive of the related volume impact also had a positive impact on gross margin 81 million pricing changes including rebates exclusive of the related volume impact adversely impacted gross margin 211 million driven in part by customer and product mix the adverse impact of these 15table of contents cardinal health inc and subsidiariesfinancial review continuedpricing changes was offset by sourcing programs and other sources of margin as a result of significant market softness gross margin from our nuclear pharmacy services division decreased by 71 million in fiscal 2013distribution selling general and administrative sgampa expenses sgampa expenses changein millions2014 2013 2012 2014 2013sgampa expenses3028 2875 2677 5 7sgampa expenses increased during fiscal 2014 over fiscal 2013 primarily due to acquisitions 129 millionsgampa expenses increased during fiscal 2013 over fiscal 2012 primarily due to acquisitions 84 million and investment spending 17 millionsegment profit and consolidated operating earnings segment profit andoperating earnings changein millions2014 2013 2012 2014 2013pharmaceutical1745 1734 1558 1 11 medical444 372 332 19 12 total segment profit2189 2106 1890 4 11 corporate304 1110 98 nm nmtotal operating earnings1885 996 1792 89 44segment profitwe evaluate segment performance based upon segment profit among other measures see note 15 of the notes to consolidated financial statements for additional information on segment profitpharmaceutical segment profitthe increase in fiscal 2014 over fiscal 2013 reflected the positive impact of sales growth which primarily reflects growth from existing customers and was largely offset by the impact of the walgreens contract expiration the impact of gross margin rate apart from the impact of the walgreens contract expiration was flat for fiscal 2014 gross margin rate was positively impacted by strong performance from generic programs including the impact of generic pharmaceutical price appreciation and was adversely impacted by customer pricing changesthe principal drivers for the increase in fiscal 2013 over fiscal 2012 were strong performance in our generic pharmaceutical programs and increased margin from branded pharmaceutical distribution agreements these benefits were partially offset by the unfavorable impact of pharmaceutical distribution pricing changes and significant market softness in our nuclear pharmacy services division medical segment profitthe principal driver for the increase in fiscal 2014 over fiscal 2013 was the positive impact of acquisitionsthe principal drivers for the increase in fiscal 2013 over fiscal 2012 were the positive impact of acquisitions and decreased cost of commodities used in our selfmanufactured products partially offset by the unfavorable impact of pricing changes driven in part by customer and product mix segment profit was also moderated by softness in proceduralbased utilization the 23 percent excise tax on certain manufactured or imported medical devices that became effective january 1 2013 had a slightly unfavorable impact on segment profitcorporateas discussed further below the principal driver for the change in corporate in fiscal 2014 and fiscal 2013 was an 829 million noncash goodwill impairment charge recognized in fiscal 2013 related to our nuclear pharmacy services divisionconsolidated operating earningsin addition to revenue gross margin and sgampa expenses discussed above operating earnings were impacted by the followingin millions2014 2013 2012restructuring and employee severance31 71 21amortization and other acquisitionrelated costs223 158 33impairments and loss on disposal of assets15 859 21litigation recoveriescharges net21 38 3restructuring and employee severancein addition to other restructuring activities during fiscal 2014 and 2013 we recognized restructuring costs of 10 million and 40 million respectively related to the restructuring plan in our medical segment we also recognized 11 million of employeerelated costs related to a restructuring plan within our nuclear pharmacy services division during the fourth quarter of fiscal 2013amortization and other acquisitionrelated costsamortization of acquisitionrelated intangible assets was 187 million 118 million and 78 million for fiscal 2014 2013 and 2012 respectively the increase in amortization during 2014 and 2013 was primarily due to intangible assets from the acquisition of assuramed we also recognized transaction costs associated with the purchase of assuramed of 20 million during fiscal 2013amortization and other acquisitionrelated costs for fiscal 2012 included income recognized upon adjustment of the contingent consideration obligation incurred in connection with the healthcare solutions holding llc p4 healthcare acquisition 71 million in early fiscal 2013 we terminated and settled the remaining contingent consideration obligation for 4 million16table of contents cardinal health inc and subsidiariesfinancial review continuedimpairments and loss on disposal of assetsduring fiscal 2014 we recognized an 8 million loss to write down property in waukegan illinois in connection with our medical segment restructuring planalso in connection with our medical segment restructuring plan during fiscal 2013 we recognized an 11 million loss to write down our gamma sterilization assets in el paso texas during fiscal 2013 we recognized an 829 million 799 million net of tax goodwill impairment charge related to our nuclear pharmacy services division as discussed further in the overview section and in note 5 of the notes to consolidated financial statements we also recognized an 8 million loss during fiscal 2013 to write down commercial software under development within our pharmaceutical segmentduring fiscal 2012 we recognized a 16 million loss to write down an indefinitelife intangible asset related to the p4 healthcare trade namelitigation recoveriescharges netwe recognized income resulting from settlements of class action antitrust claims in which we were a class member of 24 million and 38 million during fiscal 2014 and 2013 respectivelyearnings before income taxes and discontinued operationsin addition to the items discussed above earnings before income taxes and discontinued operations were impacted by the following earnings before income taxesand discontinued operations changein millions2014 2013 2012 2014 2013other income net46 15 1 nm nminterest expense net133 123 95 8 29other income netother income net for fiscal 2014 included a 32 million pretax gain related to the sale of our minority equity interests in two investmentsinterest expense netthe increase in interest expense net for fiscal 2014 and 2013 was primarily due to 13 billion of notes issued in connection with the assuramed acquisition in fiscal 2013 provision for income taxesgenerally fluctuations in the effective tax rate are due to changes within international and us state effective tax rates resulting from our business mix and discrete items a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate from continuing operations is as follows see note 8 of the notes to consolidated financial statements for a detailed disclosure of the effective tax rate reconciliation 2014 2013 2012provision at federal statutory rate350  350  350 state and local income taxes net of federal benefit22 25 23foreign tax rate differential12 40 22nondeductiblenontaxable items02 05 nondeductible goodwill impairment 332 change in measurement of an uncertain tax position and impact of irs settlements04 57 09other01 18 10effective income tax rate353  623  370 fiscal 2014 compared to fiscal 2013the fiscal 2014 effective tax rate was impacted by net favorable discrete items of 37 million which reduced the rate by 21 percentage points the discrete items include the favorable impact of the settlement of federal and state tax controversies 80 million and release of valuation allowances 12 million and the unfavorable impact of remeasurement of unrecognized tax benefits 65 million primarily as a result of proposed assessments of additional taxfiscal 2013 compared to fiscal 2012the fiscal 2013 effective tax rate was unfavorably impacted by 332 percentage points 295 million due to the nondeductibility of substantially all of the goodwill impairment which was partially offset by the favorable impact of the revaluation of our deferred tax liability and related interest on unrepatriated foreign earnings as a result of an agreement with tax authorities 64 million or 72 percentage pointsongoing auditsduring fiscal 2014 the us internal revenue service irs closed audits of fiscal years 2003 through 2005 the irs is currently conducting audits of fiscal years 2006 through 2010liquidity and capital resourceswe currently believe that based upon available capital resources cash on hand and access to committed credit facilities and projected operating cash flow we have adequate capital resources to fund working capital needs currently anticipated capital expenditures business growth and expansion contractual obligations tax payments and current and projected debt service requirements dividends and share repurchases if we decide to engage in one or more additional 17table of contents cardinal health inc and subsidiariesfinancial review continuedacquisitions depending on the size and timing of such transactions we may need to access capital in addition to cash on hand and our existing committed credit facilitiescash and equivalentsour cash and equivalents balance was 29 billion at june 30 2014 compared to 19 billion at june 30 2013 at june 30 2014 our cash and equivalents were held in cash depository accounts with major banks or invested in high quality shortterm liquid investments the increase in cash and equivalents during fiscal 2014 was driven by net cash provided by operating activities of 25 billion which was deployed for share repurchases 673 million acquisitions 519 million and dividends 415 million as anticipated net cash provided by operating activities benefited from a net working capital decrease in excess of 500 million as a result of the walgreens contract expirationduring fiscal 2013 we deployed 22 billion of cash on acquisitions 450 million on share repurchases and 353 million on dividends during fiscal 2013 we received net proceeds from longterm obligations of 981 millionduring fiscal 2012 we deployed 450 million of cash on share repurchases 300 million on dividends 260 million on capital expenditures and 174 million on acquisitions during fiscal 2012 we received net proceeds from longterm obligations of 290 millionour working capital can vary significantly depending on factors such as customer payments of accounts receivable the timing of inventory purchases and payments to vendors in the regular course of business the decrease in net working capital at june 30 2014 compared to june 30 2013 is primarily a result of the walgreens contract expirationthe cash and equivalents balance at june 30 2014 included 420 million of cash held by subsidiaries outside of the united states although the vast majority of this cash is available for repatriation permanently bringing the money into the united states could trigger us federal state and local income tax obligations as a us parent company we may temporarily access cash held by our foreign subsidiaries without becoming subject to us federal income tax through intercompany loanscredit facilities and commercial paperon october 15 2013 we reduced our committed receivables sales facility program through cardinal health funding llc chf from 950 million to 700 million in light of the walgreens contract expiration in addition to our committed receivables sales facility program our sources of liquidity include a 15 billion revolving credit facility and a commercial paper program of up to 15 billion backed by the revolving credit facilitywe had no outstanding balance under the revolving credit facility at june 30 2014 and 2013 except for standby letters of credit  of zero and 43 million at june 30 2014 and 2013 respectively we had no outstanding borrowings from the commercial paper program at june 30 2014 and 2013 we had no outstanding balance under the committed receivables sales facility program at june 30 2014 and 2013 except for standby letters of credit of 41 million and zero at june 30 2014 and 2013 respectively our revolving credit facility and committed receivables sales facility program require us to maintain a consolidated interest coverage ratio as of any fiscal quarter end of at least 4to1 and a consolidated leverage ratio of no more than 325to1 as of june 30 2014 we were in compliance with these financial covenantsavailableforsale securitiesduring fiscal 2014 we purchased 100 million of marketable securities which are classified as availableforsalelongterm obligations and other shortterm borrowingsat june 30 2014 we had total longterm obligations and other shortterm borrowings of 40 billion compared to 39 billion at june 30 2013capital expenditurescapital expenditures during fiscal 2014 2013 and 2012 were 249 million 195 million and 260 million respectivelywe expect capital expenditures in fiscal 2015 to be between 335 million to 365 million primarily for growth projects in our core businesses as well as information technology projectsdividendsduring fiscal 2014 we paid quarterly dividends totaling 121 per share an increase of 18 percent from fiscal 2013 on may 7 2014 our board of directors approved a 13 percent increase in our quarterly dividend to 03425 per share or 137 per share on an annualized basis which was paid on july 15 2014 to shareholders of record on july 1 2014on august 6 2014 our board of directors approved a quarterly dividend of 03425 per share or 137 per share on an annualized basis payable on october 15 2014 to shareholders of record on october 1 2014share repurchasesduring fiscal 2014 we repurchased 673 million of our common shares we funded the repurchases with cash on hand at june 30 2014 we had 727 million remaining under our current repurchase authorization which expires december 31 2016 on august 6 2014 our board of directors authorized an additional 10 billion under this share repurchase programinterest rate and currency risk managementwe use interest rate swaps foreign currency contracts and commodity contracts to manage our exposure to cash flow variability we also use interest rate swaps to protect the value of our debt and foreign currency forward contracts to protect the 18table of contents cardinal health inc and subsidiariesfinancial review continuedvalue of our existing foreign currency assets and liabilities see 